8 no. 5, pp. 615–626, 2009. [38] K. M. Doyle, D. Kennedy, A. M. Gorman et al., “Unfolded pro- teins and endoplasmic reticulum stress in neurodegenerative disorders,” Journal of Cellular and Molecular Medicine, vol. 15, no. 10, pp. 2025–2039, 2011. [39] H. Chen and D. C. Chan, “Mitochondrial dynamics—fusion, ﬁssion, movement, and mitophagy—in neurodegenerative diseases,” Human Molecular Genetics, vol. 18, no. 2, pp. R169– R176, 2009. [40] S. A. Detmer and D. C. Chan, “Functions and dysfunctions of mitochondrial dynamics,” Nature Reviews Molecular Cell Biology, vol. 8, no. 11, pp. 870–879, 2007. [41] K. Okamoto and J. M. Shaw, “Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes,” Annual Review of Genetics, vol. 39, pp. 503–536, 2005. [42] D. H. Cho, T. Nakamura, J. Fang et al., “β-Amyloid-related mitochondrial ﬁssion and neuronal injury,” Science, vol. 324, no. 5923, pp. 102–105, 2009. [43] S. A. Frautschy and G. M. Cole, “Why pleiotropic interven- tions are needed for alzheimer’s disease,” Molecular Neurobiol- ogy, vol. 41, no. 2-3, pp. 392–409, 2010. [44] G. N. Patrick, L. Zukerberg, M. Nikolic, S. De La Monte, P. Dikkes, and L. H. Tsai, “Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration,” Nature, vol. 402, no. 6762, pp. 615–622, 1999. [45] T. Ohshima, J. M. Ward, C. G. Huh et al., “Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 11173–11178, 1996. [46] Z. Xie, K. Sanada, B. A. Samuels, H. Shih, and L. H. Tsai, “Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration,” Cell, vol. 114, no. 4, pp. 469–482, 2003. [47] Y. Kim, J. Y. Sung, I. Ceglia et al., “Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology,” Nature, vol. 442, no. 7104, pp. 814–817, 2006. [48] L. Bertram, C. M. Lill, and R. E. Tanzi, “The genetics of alzheimer disease: back to the future,” Neuron, vol. 68, no. 2, pp. 270–281, 2010. [49] A. J. Abrams, A. Farooq, and G. Wang, “S-nitrosylation of ApoE in Alzheimer’s disease,” Biochemistry, vol. 50, no. 17, pp. 3405–3407, 2011. [50] R. Mayeux, K. Marder, and L. J. Cote, “The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan,” American Journal of Epidemiology, vol. 142, no. 8, pp. 820–827, 1988–1993. [51] B. I. Giasson and V. M. Y. Lee, “Are ubiquitination pathways central to Parkinson’s disease?” Cell, vol. 114, no. 1, pp. 1–8, 2003. [52] P. Jenner, “Oxidative stress in Parkinson’s disease,” Annals of Neurology, vol. 53, supplement 3, pp. S26–S36, 2003. [53] R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, “Chronic systemic pesticide exposure reproduces features of Parkinson’s disease,” Nature Neuroscience, vol. 3, no. 12, pp. 1301–1306, 2000. [54] J. W. Langston, “Parkinson’s disease: current and future chal- lenges,” NeuroToxicology, vol. 23, no. 4-5, pp. 443–450, 2002. [55] R. L. Miller, M. James-Kracke, G. Y. Sun, and A. Y. Sun, “Oxidative and inﬂammatory pathways in parkinson’s dis- ease,” Neurochemical Research, vol. 34, no. 1, pp. 55–65, 2009. [56] T. Kitada, S. Asakawa, N. Hattori et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,” International Journal of Cell Biology Nature, vol. 392, no. 6676, pp. 605–608, 1998. [57] C. B. Lucking, A. Durr, V. Bonifati et al., “Association between early-onset Parkinson’s disease and mutations in the parkin gene,” The New England Journal of Medicine, vol. 342, no. 21, pp. 1560–1567, 2000. [58] S. A. Oliveira, W. K. Scott, E. R. Martin et al., “Parkin muta- tions and susceptibility alleles in late-onset Parkinson’s dis- ease,” Annals of Neurology, vol. 53, no. 5, pp. 624–629, 2003. [59] H. Shimura, N. Hattori, S. I. Kubo et al., “Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase,” Nature Genetics, vol. 25, no. 3, pp. 302–305, 2000. [60] H. Jiang, Y. Ren, J. Zhao, and J. Feng, “Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis,” Human Molecular Genetics, vol. 13, no. 16, pp. 1745–1754, 2004. [61] T. M. Dawson and V. L. Dawson, “Molecular pathways of neurodegeneration in Parkinson’s disease,” Science, vol. 302, no. 5646, pp. 819–822, 2003. [62] M. B. Feany and L. J. Pallanck, “Parkin: a multipurpose neu- roprotective agent?” Neuron, vol. 38, no. 1, pp. 13–16, 2003. [63] R. Von Coelln, V. L. Dawson, and T. M. Dawson, “Parkin- associated Parkinson’s disease,” Cell and Tissue Research, vol. 318, no. 1, pp. 175–184, 2004. [64] N. F. Bence, R. M. Sampat, and R. R. Kopito, “Impairment of the ubiquitin-proteasome system by protein aggregation,” Science, vol. 292, no. 5521, pp. 1552–1555, 2001. [65] E. Masliah, E. Rockenstein, I. Veinbergs et al., “Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders,” Science, vol. 287, no. 5456, pp. 1265–1269, 2000. [66] C. A. da Costa, C. Sunyach, E. Giaime et al., “Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson’s dis- ease,” Nature Cell Biology, vol. 11, no. 11, pp. 1370–1375, 2009. [67] C. Alves da Costa and F. Checler, “Apoptosis in Parkinson’s disease: is p53 the missing link between genetic and sporadic Parkinsonism?” Cellular Signalling, vol. 23, no. 6, pp. 963–968, 2011. [68] D. Yao, Z. Gu, T. Nakamura et al., “Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regu- lates its E3 ubiquitin ligase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10810–10814, 2004. [69] K. K. K. Chung, B. Thomas, X. Li et al., “S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function,” Science, vol. 304, no. 5675, pp. 1328– 1331, 2004. [70] G. R. Sue, Z. C. Ho, and K. Kim, “Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling,” Free Radical Biology and Medicine, vol. 38, no. 12, pp. 1543–1552, 2005. [71] S. G. Rhee, S. W. Kang, W. Jeong, T. S. Chang, K. S. Yang, and H. A. Woo, “Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins,” Current Opinion in Cell Biology, vol. 17, no. 2, pp. 183–189, 2005. [72] Z. A. Wood, E. Schro¨der, J. R. Harris, and L. B. Poole, “Structure, mechanism and regulation of peroxiredoxins,” Trends in Biochemical Sciences, vol. 28, no. 1, pp. 32–40, 2003. [73] S. H. Kim, M. Fountoulakis, N. Cairns, and G. Lubec, “Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down Syndrome,” Journal of Neural Transmission, Supplement, no. 61, pp. 223–235, 2001. [74] K. Krapfenbauer, E. Engidawork, N. Cairns, M. Fountoulakis,